Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00462657|
Recruitment Status : Unknown
Verified September 2007 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : April 19, 2007
Last Update Posted : August 26, 2013
RATIONALE: Studying ways to diagnose fungal infections early may help doctors plan the best treatment.
PURPOSE: This clinical trial is studying laboratory tests to see how well they find aspergillosis early in patients at high risk of fungal infection caused by treatment for hematologic cancer or other disease.
|Condition or disease||Intervention/treatment||Phase|
|Graft Versus Host Disease Infection Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms||Genetic: polymerase chain reaction Other: bronchoalveolar lavage Other: immunoenzyme technique Other: laboratory biomarker analysis Procedure: bronchoscopy Procedure: management of therapy complications||Not Applicable|
- Determine the test characteristics of galactomannan (GM) ELISA using serum and bronchoalveolar lavage fluid (BALF) collected from patients at high risk of invasive fungal infection.
- Determine the test characteristics of aspergillus PCR using blood and BALF samples collected from these patients.
- Evaluate the role of noninvasive exhaled breath condensate (EBC) in detecting invasive aspergillosis (IA).
- Determine whether repeated measures over time or a combination of markers improves the test characteristics.
- Establish cutoff points for the diagnosis of IA.
- Determine the inflammatory marker and cytokine profile of EBC in fungal infection and after bone marrow transplantation as a marker of acute lung injury.
- Assess the role of bronchoscopy with bronchoalveolar lavage in identifying the causal pathogen early in the disease course of febrile neutropenic patients.
- Assess the role of GM ELISA in prognosis and response to treatment for IA.
- Assess the role of aspergillus PCR in prognosis and response to treatment for IA.
OUTLINE: This is a prospective study.
Patients are assessed for early diagnosis of invasive aspergillosis (IA) using serum and bronchoalveolar lavage fluid (BALF) evaluated by ELISA for galactomannan (GM) antigen and real time PCR for fungal DNA. Serum samples are collected at baseline and periodically during study, beginning with the onset of neutropenia and continuing until resolution of fever or recovery of neutrophil count. BALF samples are collected in patients with abnormal chest radiology evaluated by bronchoscopy and bronchoalveolar lavage. BALF is analyzed for GM antigen, fungal DNA, inflammatory markers, and cytokines.
Patients are also assessed using exhaled breath condensate (EBC) evaluated by GM ELISA and real time PCR. EBC is collected at baseline and periodically during study to detect GM antigen or fungal DNA and to measure markers of pulmonary inflammation and oxidative stress (e.g., pH, hydrogen peroxide, and leukotriene B4).
PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Official Title:||Early Diagnosis of Invasive Aspergillosis in a High Risk Group of Patients Using Serum and Bronchoalveolar Lavage Fluid Real Time PCR and Galactomannan ELISA|
|Study Start Date :||July 2005|
- Sensitivity and specificity of galactomannan (GM) ELISA and real time PCR in detecting invasive aspergillosis (IA)
- Diagnostic value of IA screening by GM ELISA and real time PCR, in terms of positive and negative predicative values
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00462657
|Saint Bartholomew's Hospital||Recruiting|
|London, England, United Kingdom, EC1A 7BE|
|Contact: Samir G Agrawal, MD, PhD 44-207-601-8202 email@example.com|
|Royal Brompton Hospital||Recruiting|
|London, England, United Kingdom, SW3 6NP|
|Contact: Mark Grifiths, MD 44-20-7351-8523|
|Study Chair:||Samir G Agrawal, MD, PhD||St. Bartholomew's Hospital|